(Q40657508)

22 September 2017

title

The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. (English)

1 reference

22 September 2017

R Jake Jacobs

1

1 reference

22 September 2017

Raymond S Koff

series ordinal

2

1 reference

22 September 2017

Allen S Meyerhoff

series ordinal

3

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

The American Journal of Gastroenterology

22 September 2017

published in

1 reference

22 September 2017

volume

97

1 reference

22 September 2017

issue

2

1 reference

22 September 2017

page(s)

427-434

1 reference

Fulminant hepatitis A in intravenous drug users with chronic liver disease.

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05481.X

Acute hepatitis A in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05481.X

The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05481.X

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05481.X

The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05481.X

Duration of protection from clinical hepatitis A disease after vaccination with VAQTA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05481.X

Inactivated hepatitis A vaccine: long-term antibody persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05481.X

Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05481.X

The cost of hepatitis A infections in American adolescents and adults in 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05481.X

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05481.X

Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05481.X

Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05481.X

Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05481.X

Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05481.X

10.1111/J.1572-0241.2002.05481.X

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference